Interventional radiology and the pancreatic cancer patient

Cancer Journal (United States)

Volumn 18, Issue 6, 2012, Pages 591-601

  Brown, Daniel B ^a   Narayanan, Govindarajan ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

biliary stent; chemoembolization; embolization; interventional radiology; irreversible electroporation; Pancreatic cancer; percutaneous abscess drainage; percutaneous biliary drainage; radioembolization; radiofrequency ablation

Indexed keywords

BILIRUBIN;

ABDOMINAL ABSCESS; ABLATION THERAPY; ADJUVANT THERAPY; ANASTOMOSIS LEAKAGE; BILE LEAKAGE; BILIARY TRACT DRAINAGE; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CATHETERIZATION; CHEMOEMBOLIZATION; CHOLESTASIS; CYTOREDUCTIVE SURGERY; ELECTROPORATION; HUMAN; INTERVENTIONAL RADIOLOGY; METAL STENT; MORBIDITY; PANCREAS CANCER; PANCREAS RESECTION; PERCUTANEOUS DRAINAGE; PERCUTANEOUS TRANSHEPATIC DRAINAGE; PEROPERATIVE COMPLICATION; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; REVIEW; STOMACH EMPTYING; SURGICAL MORTALITY; TUMOR ABLATION;

HUMANS; PALLIATIVE CARE; PANCREATIC NEOPLASMS; RADIOLOGY, INTERVENTIONAL; TREATMENT OUTCOME;

EID: 84871222254     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e3182745bee     Document Type: Review

References (73)

1. Bramhall SR, Allum WH, Jones AG, et al. Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study. Br J Surg. 1995;82: 111-115.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-66.
3. Sohn TA, Yeo CJ, Cameron JL, et al. Pancreaticoduodenectomy: role of interventional radiologists in managing patients and complications. J Gastrointest Surg. 2003;7:209-219.
4. Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreasV616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000;4:567-579.
5. Wente MN, Veit JA, Bassi C, et al. Postpancreatectomy hemorrhage (PPH): an International Study Group of Pancreatic Surgery (ISGPS) definition. Surgery. 2007;142:20-25.
6. Yekebas EF, Wolfram L, Cataldegirmen G, et al. Postpancreatectomy hemorrhage: diagnosis and treatment: an analysis in 1669 consecutive pancreatic resections. Ann Surg. 2007;246:269-280.
7. Sener SF, Fremgen A, Menck HR, et al. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg. 1999;189:1-7.
8. Cronin CG, Gervais DA, Castillo CF, et al. Interventional radiology in the management of abdominal collections after distal pancreatectomy: a retrospective review. AJR Am J Roentgenol. 2011;197:241-246.
9. Ferrone CR, Warshaw AL, Rattner DW, et al. Pancreatic fistula rates after 462 distal pancreatectomies: staplers do not decrease fistula rates. J Gastrointest Surg. 2008;12:1691-1697; discussion 1697-1698.
10. Kleeff J, Diener MK, Z'Graggen K, et al. Distal pancreatectomy: risk factors for surgical failure in 302 consecutive cases. Ann Surg. 2007; 245:573-582.
11. Knaebel HP, Diener MK, Wente MN, et al. Systematic review and meta-analysis of technique for closure of the pancreatic remnant after distal pancreatectomy. Br J Surg. 2005;92:539-546.
12. Bassi C, Dervenis C, Butturini G, et al. Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery. 2005;138:8-13.
13. Koch M, Garden OJ, Padbury R, et al. Bile leakage after hepatobiliary and pancreatic surgery: a definition and grading of severity by the International Study Group of Liver Surgery. Surgery. 2011;149:680-688.
14. Saad WE, Wallace MJ, Wojak JC, et al. Quality improvement guidelines for percutaneous transhepatic cholangiography, biliary drainage, and percutaneous cholecystostomy. J Vasc Interv Radiol. 2010;21:789-795.
15. Puppala S, Patel J, McPherson S, et al. Hemorrhagic complications after Whipple surgery: imaging and radiologic intervention. AJR Am J Roentgenol. 2011;196:192-197.
16. Hur S, Yoon CJ, Kang SG, et al. Transcatheter arterial embolization of gastroduodenal artery stump pseudoaneurysms after pancreaticoduo-denectomy: safety and efficacy of two embolization techniques. J Vasc Interv Radiol. 2011;22:294-301.
17. Heiss P, Bachthaler M, Hamer OW, et al. Delayed visceral arterial hemorrhage following Whipple's procedure: minimally invasive treatment with covered stents. Ann Surg Oncol. 2008;15:824-832.
18. Kim KR, Shin JH, Han YM, et al. Percutaneous self-expandable metallic stent placement for cancer recurrence at the hepaticojejunostomy site. J Vasc Interv Radiol. 2008;19:1454-1459.
19. Krokidis M, Fanelli F, Orgera G, et al. Percutaneous palliation of pancreatic head cancer: randomized comparison of ePTFE/FEP-covered versus uncovered nitinol biliary stents. Cardiovasc Intervent Radiol. 2011;34:352-361.
20. Schoder M, Rossi P, Uflacker R, et al. Malignant biliary obstruction: treatment with ePTFE-FEPYcovered endoprostheses initial technical and clinical experiences in a multicenter trial. Radiology. 2002;225:35-42.
21. Thornton RH, Ulrich R, Hsu M, et al. Outcomes of patients undergoing percutaneous biliary drainage to reduce bilirubin for administration of chemotherapy. J Vasc Interv Radiol. 2012;23:89-95.
22. Saad WE. Transhepatic techniques for accessing the biliary tract. Tech Vasc Interv Radiol. 2008;11:21-42.
23. Saad WE, Davies MG, Darcy MD. Management of bleeding after percutaneous transhepatic cholangiography or transhepatic biliary drain placement. Tech Vasc Interv Radiol. 2008;11:60-71.
24. Coons HG. Self-expanding stainless steel biliary stents. Radiology. 1989;170:979-983.
25. Irving JD, Adam A, Dick R, et al. Gianturco expandable metallic biliary stents: results of a European clinical trial. Radiology. 1989;172: 321-326.
26. Lammer J, Hausegger KA, Fluckiger F, et al. Common bile duct obstruction due to malignancy: treatment with plastic versus metal stents. Radiology. 1996;201:167-172.
27. Bezzi M, Zolovkins A, Cantisani V, et al. New ePTFE/FEP-covered stentin the palliative treatment of malignant biliary obstruction. J Vasc Interv Radiol. 2002;13:581-589.
28. Hatzidakis A, Krokidis M, Kalbakis K, et al. ePTFE/FEP-covered metallic stents for palliation of malignant biliary disease: can tumor ingrowth be prevented? Cardiovasc Intervent Radiol. 2007;30:950-958.
29. Sut M, Kennedy R, McNamee J, et al. Long-term results of percutaneous transhepatic cholangiographic drainage for palliation of malignant biliary obstruction. J Palliat Med. 2011;13:1311-1313.
30. Bakhru M, Ho HC, Gohil V, et al. Fully-covered, self-expandable metal stents (CSEMS) in malignant distal biliary strictures: mid-term evaluation. J Gastroenterol Hepatol. 2011;26:1022-1027.
31. Fanelli F, Orgera G, Bezzi M, et al. Management of malignant biliary obstruction: technical and clinical results using an expanded polytetrafluoroethylene fluorinated ethylene propylene (ePTFE/FEP)Y covered metallic stent after 6-year experience. Eur Radiol. 2008;18: 911-919.
32. Saleem A, Leggett CL, Murad MH, et al. Meta-analysis of randomized trials comparing the patency of covered and uncovered self-expandable metal stents for palliation of distal malignant bile duct obstruction. Gastrointest Endosc. 2011;74:321-327, e321-e323.
33. Carrasco CH, Zornoza J, Bechtel WJ. Malignant biliary obstruction: complications of percutaneous biliary drainage. Radiology. 1984;152: 343-346.
34. Hamlin JA, Friedman M, Stein MG, et al. Percutaneous biliary drainage: complications of 118 consecutive catheterizations. Radiology. 1986;158:199-202.
35. Savader SJ, Trerotola SO, Merine DS, et al. Hemobilia after percutaneous transhepatic biliary drainage: treatment with transcatheter embolo-therapy. J Vasc Interv Radiol. 1992;3:345-352.
36. Cleary SP, Gryfe R, Guindi M, et al. Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors. J Am Coll Surg. 2004;198:722-731.
37. Matsuno S, Egawa S, Fukuyama S, et al. Pancreatic Cancer Registry in Japan: 20 years of experience. Pancreas. 2004;28:219-230.
38. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403-2413.
39. Poplin E, Feng Y, Berlin J, et al. Phase III, randomized study of gem-citabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2009;27:3778-3785.
40. Ho AS, Picus J, Darcy MD, et al. Long-term outcome after chemoem-bolization and embolization of hepatic metastatic lesions from neuroen-docrine tumors. AJR Am J Roentgenol. 2007;188:1201-1207.
41. Sharma KV, Gould JE, Harbour JW, et al. Hepatic arterial chemoembo-lization for management of metastatic melanoma. AJR Am J Roent-genol. 2008;190:99-104.
42. Stuart JE, Tan B, Myerson RJ, et al. Salvage radioembolization of liver-dominant metastases with a resin-based microsphere: initial outcomes. J Vasc Interv Radiol. 2008;19:1427-1433.
43. Kim JH, Choi EK, Yoon HK, et al. Transcatheter arterial chemoembo-lization for hepatic recurrence after curative resection of pancreatic adenocarcinoma. Gut Liver. 2010;4:384-388.
44. Brown DB, Gonsalves CF, Yeo CJ, et al. One year survival with poorly differentiated metastatic pancreatic carcinoma following chemoemboli-zation with gemcitabine and cisplatin. Oncol Rep. 2010;24:767-769.
45. Cao C, Yan TD, Morris DL, et al. Radioembolization with yttrium-90 microspheres for pancreatic cancer liver metastases: results from a pilot study. Tumori. 2010;96:955-958.
46. Kim W, Clark TW, Baum RA, et al. Risk factors for liver abscess formation after hepatic chemoembolization. J Vasc Interv Radiol. 2001;12: 965-968.
47. Patel S, Tuite CM, Mondschein JI, et al. Effectiveness of an aggressive antibiotic regimen for chemoembolization in patients with previous biliary intervention. J Vasc Interv Radiol. 2006;17:1931-1934.
48. Geschwind JF, Kaushik S, Ramsey DE, et al. Influence of a new prophylactic antibiotic therapy on the incidence of liver abscesses after che-moembolization treatment of liver tumors. J Vasc Interv Radiol. 2002; 13:1163-1166.
49. Khan W, Sullivan KL, McCann JW, et al. Moxifloxacin prophylaxis for chemoembolization or embolization in patients with previous biliary interventions: a pilot study. AJR Am J Roentgenol. 2011;197: W343-W345.
50. Park JB, Kim YH, Kim J, et al. Radiofrequency ablation of liver metastasis in patients with locally controlled pancreatic ductal adenocarci-noma. J Vasc Interv Radiol. 2012;23:635-641.
51. Callery MP, Chang KJ, Fishman EK, et al. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol. 2009;16:1727-1733.
52. Conroy T, Desseigne F, Ychou M, et al. Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817-1825.
53. Loehrer PJ Sr, Feng Y, Cardenes H, et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group Trial. J Clin Oncol. 2011;29:4105-4112.
54. Huguet F, André T, Hammel P, et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic ade-nocarcinoma in GERCOR phase II and III studies. J Clin Oncol. 2007;25:326-331.
55. Pezzilli R, Serra C, Ricci C, et al. Radiofrequency ablation for advanced ductal pancreatic carcinoma: is this approach beneficial for our patients? A systematic review. Pancreas. 2011;40:163-165.
56. Girelli R, Frigerio I, Salvia R, et al. Feasibility and safety of radiofre-quency ablation for locally advanced pancreatic cancer. Br J Surg. 2010;97:220-225.
57. Hadjicostas P, Malakounides N, Varianos C, et al. Ablation in pancreatic cancer. HPB (Oxford). 2006;8:61-64.
58. D'Onofrio M, Barbi E, Girelli R, et al. Radiofrequency ablation of locally advanced pancreatic adenocarcinoma: an overview. World J Gas-troenterol. 2010;16:3478-3483.
59. Lygidakis NJ, Sharma SK, Papastratis P, et al. Microwave ablation in locally advanced pancreatic carcinomaVa new look. Hepatogastroenter-ology. 2007;54:1305-1310.
60. Thanos L, Poulou LS, Mailli L, et al. Image-guided radiofrequency ablation of a pancreatic tumor with a new triple spiral shaped electrode. Cardiovasc Intervent Radiol. 2010;33:215-218.
61. Wu Y, Tang Z, Fang H, et al. High operative risk of cool-tip radiofre-quency ablation for unresectable pancreatic head cancer. J Surg Oncol. 2006;94:392-395.
62. Li J, Chen X, Yang H, et al. Tumour cryoablation combined with palliative bypass surgery in the treatment of unresectable pancreatic cancer: a retrospective study of 142 patients. Postgrad Med J. 2011;87:89-95.
63. Maor E, Ivorra A, Leor J, et al. The effect of irreversible electroporation on blood vessels. Technol Cancer Res Treat. 2007;6:307-312.
64. José A, Sobrevals L, Ivorra A, et al. Irreversible electroporation shows efficacy against pancreatic carcinoma without systemic toxicity in mouse models. Cancer Lett. 2012;317:16-23.
65. Charpentier KP, Wolf F, Noble L, et al. Irreversible electroporation of the pancreas in swine: a pilot study. HPB (Oxford). 2010;12:348-351.
66. Bower M, Sherwood L, Li Y, et al. Irreversible electroporation of the pancreas: definitive local therapy without systemic effects. J Surg Oncol. 2011;104:22-28.
67. Lee EW, Loh CT, Kee ST. Imaging guided percutaneous irreversible elec-troporation: ultrasound and immunohistological correlation. Technol Cancer Res Treat. 2007;6:287-293.
68. Bertacchini C, Margotti PM, Bergamini E, et al. Design of an irreversible electroporation system for clinical use. Technol Cancer Res Treat. 2007;6:313-320.
69. Thomson KR, Cheung W, Ellis SJ, et al. Investigation of the safety of irreversible electroporation in humans. J Vasc Interv Radiol. 2011;22:611-621.
70. Pech M, Janitzky A, Wendler JJ, et al. Irreversible electroporation of renal cell carcinoma: a first-in-man phase I clinical study. Cardiovasc Intervent Radiol. 2011;34:132-138.
71. Bagla S, Papadouris D. Percutaneous irreversible electroporation of surgically unresectable pancreatic cancer: a case report. J Vasc Interv Ra-diol. 2012;23:142-145.
72. Narayanan G, Yrizarry J, Perez-Rojas E, et al. Safety and efficacy of irreversible electroporation in the treatment of primary HCC. J Vasc Interv Radiol. 2011;22:S63-S64.
73. Martin RC 2nd, McFarland K, Ellis S, et al. Irreversible electroporation therapy in the management of locally advanced pancreatic adenocarcinoma [published online ahead of print]. J Am Coll Surg. 2012;215:361-369.